Cambrex
CBM | US
Overview
Corporate Details
- ISIN(s):
- US1320111073
- LEI:
- 4Q9DLX2VIFGJMOYJ4Y35
- Country:
- United States of America
- Address:
- N/A
- Website:
- https://www.cambrex.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Cambrex filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cambrex
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cambrex via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops diagnostics and targeted therapies to personalize platinum-based cancer treatments.
Sweden
CHOSA
Sweden
CHOSA
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Japan
4519
Direct-to-home service providing medicine boxes, health products, and daily necessities.
Japan
4558
Japan
4558
Developing drug-Fc conjugates as targeted immunotherapies for cancer and serious infections.
United States of America
CDTX
United States of America
CDTX
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Sweden
CINPHA
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
United States of America
CING
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
United States of America
CTOR
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR
United States of America
CTXR
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
South Korea
063160